Oseni is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 18 US drug patents filed from 2013 to 2014. Out of these, 4 drug patents are active and 14 have expired. Oseni's patents have been open to challenges since 25 January, 2017. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 04, 2029. Details of Oseni's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7807689 | Dipeptidyl peptidase inhibitors |
Jun, 2028
(3 years from now) | Active |
| US8288539 | Dipeptidyl peptidase inhibitors |
Mar, 2025
(3 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8637079 | Solid preparation comprising alogliptin and pioglitazone |
Jun, 2029
(4 years from now) | Active |
| US8173663 | Dipeptidyl peptidase inhibitors |
Mar, 2025
(3 months from now) | Active |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) |
Expired
|
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) |
Expired
|
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) |
Expired
|
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) |
Expired
|
| US6303640 | Pharmaceutical composition |
Aug, 2016
(8 years ago) |
Expired
|
| US6211205 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6166042 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6172090 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6166043 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6150384 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US5965584 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6329404 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6271243 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6150383 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oseni's patents.
Latest Legal Activities on Oseni's Patents
Given below is the list of recent legal activities going on the following patents of Oseni.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288539 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Oct, 2023 | US8173663 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Mar, 2022 | US7807689 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jul, 2021 | US8637079 |
| Expire Patent Critical | 04 Jan, 2021 | US7459428 |
| Maintenance Fee Reminder Mailed Critical | 20 Jul, 2020 | US7459428 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Apr, 2020 | US8288539 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Nov, 2019 | US8173663 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Apr, 2018 | US7807689 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Jan, 2018 | US7078381 |
FDA has granted several exclusivities to Oseni. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Oseni, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Oseni.
Exclusivity Information
Oseni holds 3 exclusivities. All of its exclusivities have expired in 2019. Details of Oseni's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
US patents provide insights into the exclusivity only within the United States, but Oseni is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oseni's family patents as well as insights into ongoing legal events on those patents.
Oseni's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Oseni's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 04, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Oseni Generics:
There are no approved generic versions for Oseni as of now.
Alternative Brands for Oseni
Oseni which is used for treating diabetes and related metabolic disorders, including glycemic and lipid metabolism abnormalities., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Oseni
Oseni is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for treating diabetes and related metabolic disorders, including glycemic and lipid metabolism abnormalities. Oseni uses Alogliptin Benzoate; Pioglitazone Hydrochloride as an active ingredient. Oseni was launched by Takeda Pharms Usa in 2013.
Can you believe Oseni received compensation for the extended wait time during the regulatory approval process?
A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.
Approval Date:
Oseni was approved by FDA for market use on 25 January, 2013.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Oseni is 25 January, 2013, its NCE-1 date is estimated to be 25 January, 2017.
Active Ingredient:
Oseni uses Alogliptin Benzoate; Pioglitazone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Alogliptin Benzoate; Pioglitazone Hydrochloride ingredient
Treatment:
Oseni is used for treating diabetes and related metabolic disorders, including glycemic and lipid metabolism abnormalities.
Dosage:
Oseni is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 12.5MG BASE;EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| EQ 25MG BASE;EQ 15MG BASE | TABLET | Prescription | ORAL |
| EQ 12.5MG BASE;EQ 30MG BASE | TABLET | Prescription | ORAL |
| EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| EQ 25MG BASE;EQ 30MG BASE | TABLET | Prescription | ORAL |
| EQ 25MG BASE;EQ 45MG BASE | TABLET | Prescription | ORAL |